Dec 06, 2022 / 01:00PM GMT
Operator
Good morning. Welcome to Sage Therapeutics and Biogen's Joint Investor Webcast. (Operator Instructions). This call is being webcast live on the Investors & Media section of Sage's and Biogen's website at sagerx.com and biogen.com, respectively. This call is the property of Sage Therapeutics and Biogen and recording reproduction or transmission of this call without the expressed written consent of Sage Therapeutics and Biogen is strictly prohibited. Please note that this call is being recorded.
I would now like to introduce Helen Rubinstein, Director, Investor Relations at Sage Therapeutics.
Helen Rubinstein - Sage Therapeutics, Inc. - IR Officer
Good morning. Mike Hencke, Head of Investor Relations at Biogen, and I are pleased to introduce Sage Therapeutics and Biogen's joint webcast focusing on the planned commercialization strategy for zuranolone in major depressive disorder, or MDD, if approved.
Before we begin, we encourage everyone to go to the Investors & Media section of our website at sagerx.com and biogen.com, where you can
SAGE Therapeutics Inc and Biogen Inc to Discuss Potential Commercialization Plans for Zuranolone Transcript
Dec 06, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers